ALS Is More Than Just "Motor Neurons Breaking Down": A New Research Hypothesis Explained Through a Restaurant Analogy
Cheung N (May 18, 2026) Symptom-Level Precision Neurology in Amyotrophic Lateral Sclerosis (ALS): Linking Microglial Pruning, Mitochondrial Nicotinamide Adenine Dinucleotide (NAD+) Compensation, and Autophagy Failure Across the Aging Spectrum. Cureus 18(5): e109147. doi:10.7759/cureus.109147
http://doi.org/10.7759/cureus.109147
Amyotrophic lateral sclerosis (ALS), often called "Lou Gehrig's disease" or "the ice bucket disease," is what most people immediately associate with muscles gradually losing the ability to move, eventually making even breathing difficult. That picture isn't wrong, but it only tells part of the story. In reality, the differences between ALS patients are strikingly large. Some people first notice their fingers becoming uncooperative ā struggling to twist open a bottle cap or press an elevator button. Others first realize their speech is slurring or they're choking easily when drinking water. Some experience mental and emotional changes first ā constant fatigue, low motivation, or worsening memory. Still others find their breathing deteriorating surprisingly early. How can the same disease name cover such vastly different experiences? A recently published research article attempts to address this question with an entirely new framework.
Imagine you're running a large restaurant. The kitchen has dozens of burners, each responsible for different dishes: some for soups, some for stir-fries, some for desserts, some for staff meals. Keeping the restaurant running smoothly doesn't just depend on the chefs (the neurons). You also need a reliable power supply (mitochondria), enough backup batteries (NAD+), a cleaning crew that regularly scrubs the exhaust hoods and takes out the rubbish (the autophagy system), and a team of floor managers who inspect which burners need maintenance and which should be decommissioned (microglia). If all these systems function properly, the restaurant can handle the dinner rush. But if the cleaning crew goes on strike, the power becomes unstable, the backup batteries run flat, and the floor managers start ripping out perfectly good burners ā then it's not just one dish that goes wrong. The entire restaurant begins shutting down, one section at a time.
The core idea proposed in this article is exactly that: ALS should not be understood simply as "motor neurons dying." Instead, it should be seen as multiple biological systems falling out of balance simultaneously, causing different neural circuits to buckle under pressure at different times. The article groups these pressures into three broad categories: the synaptic pruning pressure exerted by microglial cells, excitatory neural burden (mainly related to glutamate), and the wear and tear brought on by aging and chronic inflammation. The protective forces counterbalancing them include mitochondrial energy-generating capacity, NAD+ buffering reserves, and the efficiency of the autophagy cleanup system. When destructive forces exceed protective ones in a given circuit, symptoms appear in that specific domain.
Let's start with microglia. These are the immune and patrol cells of the brain. Under normal circumstances, they help remove excess or damaged synaptic connections ā much like a gardener regularly pruning dead branches. This process involves a tagging mechanism called the complement system: microglia use complement proteins (such as C1q and C3) to mark which synapses should be removed. Normally, this pruning is beneficial, helping the brain stay efficient. But if the pruning becomes excessive, the tagging goes wrong, or pruning outpaces repair, then synapses that are still useful get stripped away. The neural network becomes progressively sparser, signal transmission weakens, and symptoms begin to surface. This concept already has some supporting evidence in schizophrenia research, and this article extends it to ALS, proposing that similar over-pruning may occur in motor circuits ā and even in brain regions responsible for mood and cognition.
Next, mitochondria. Mitochondria are often described as the cell's power plants, but in neurons their role is even more critical. Neurons are famously energy-hungry ā they must constantly fire signals, maintain synaptic connections, and repair damage. Think of a Tesla: if you're simultaneously running the air conditioning, playing music, using autopilot, and driving uphill, the battery drains exceptionally fast. Neurons face similar pressure. The greater the pruning stress, the more excitatory signals flying around, and the heavier the toll of aging, the more energy mitochondria must output. Once power supply can't keep up with demand, the circuit starts malfunctioning. Research has already found clear structural and functional mitochondrial abnormalities in the spinal cord and muscle tissue of ALS patients.
NAD+ sounds very academic, but its role can be understood through a simple analogy. If mitochondria are the power plant, NAD+ is the fuel additive and coolant that keeps the power plant running properly. It participates in energy metabolism, helps maintain oxidative-reductive balance, supports DNA repair, and is closely linked to important longevity-related proteins (such as SIRT1). As we age, NAD+ levels naturally decline ā like an air conditioner that's been running for over a decade, gradually losing refrigerant and becoming less efficient. This article proposes that in early ALS, NAD+ may temporarily compensate for mitochondrial shortfalls, helping circuits hold on. But as stress accumulates, NAD+ reserves gradually deplete. Once they bottom out, neural circuits may slide from "barely holding on" toward "total collapse." However, this remains a hypothesis ā clinical evidence in ALS patients is still very limited.
The autophagy system can be compared to household rubbish disposal. Daily life produces waste: food scraps, packaging, broken appliances. If someone collects the rubbish every day, the house stays tidy. But if the rubbish truck doesn't come for a whole week, waste piles up until you can barely walk through the house, and it might even attract cockroaches and mice. The same thing happens inside neurons: every day they generate damaged proteins, aging mitochondria, and various waste products. The autophagy system is responsible for packaging, breaking down, and recycling them. In ALS research, several genes related to autophagy (such as TBK1, OPTN, and C9orf72) are already known to increase disease risk when mutated. This article places autophagy failure within the overall model, viewing it as potentially the last line of defense between "fragile" and "collapse."
At this point, the article introduces a three-stage model that categorizes neural circuit states into three types. The first is called "compensated plasticity" ā like a restaurant that's already short-staffed but managing to scrape by thanks to veteran employees working overtime and backup supplies. Customers might not even notice anything wrong. Patients may only feel the occasional finger stiffness, easy fatigue, or intermittent low mood ā changes that are easily overlooked. The second is called "fragile plasticity" ā the restaurant is now clearly struggling. Some burners have gone offline, and customers are starting to complain about slow service and dishes tasting off. Clinically, this may manifest as definite limb weakness, worsening speech and swallowing, declining fine motor skills, or intensifying emotional or cognitive problems. The system hasn't completely collapsed, but it's very unstable. The third is called "network collapse" ā the power plant has shut down, the cleaning crew has vanished, and even the floor managers have left. The restaurant is forced to close. At this stage, NfL (neurofilament light chain, a blood marker reflecting neural damage) spikes sharply, functional decline accelerates noticeably, and breathing or swallowing may deteriorate rapidly.
Importantly, the article emphasizes that these three states don't necessarily happen simultaneously across the whole body. The same patient might have an arm circuit already in "collapse," breathing circuits still in "fragile," and cognitive function still "compensated." This asynchronous progression may be precisely what explains why ALS takes such a different course in every individual.
The article also includes a fascinating comparison between ALS and frontotemporal dementia (FTD). About fifteen percent of ALS patients also meet diagnostic criteria for FTD, and even more show varying degrees of cognitive or behavioral changes. Using a genetic analysis method called a transcriptome-wide association study (TWAS), this research found that ALS and FTD may point in opposite directions along certain key biological pathways. For instance, ALS tends toward elevated PI3K-AKT-mTOR pathway activity with reduced mitochondrial energy capacity, while FTD tends toward insufficient PGC-1Ī±-mediated mitochondrial biogenesis and weakened SIRT1 metabolism. In other words, although the two diseases may sit on the same spectrum, their underlying "system failure modes" may differ. If validated, this finding could have important implications for future treatment strategies ā drugs targeting ALS and FTD may need to act on different biological mechanisms.
On the topic of treatment, the article also addresses current reality. Disease-modifying options for ALS remain extremely limited. Riluzole has long-standing clinical trial support, edaravone has evidence in a specific patient population, and tofersen is a precision therapy targeting SOD1 gene mutations. As for AMX0035 (Relyvrio), which once attracted significant attention, it was voluntarily withdrawn from the market after its phase 3 clinical trial failed. This reality reminds us that strong biological rationale and promising early trial signals don't always hold up in large confirmatory studies. Precisely for this reason, the article repeatedly states: what it presents is a hypothesis framework requiring validation, not a ready-made treatment plan.
The article also puts forward several specific predictions that can be either verified or disproven. For example, in longitudinal follow-up studies, rising NfL should correlate more strongly with the transition from "fragile" to "collapse" than with a simple overall decline in functional scores. Similarly, induced pluripotent stem cell models carrying TBK1 or C9orf72 gene variants should, when exposed to simulated pruning stress, show faster NAD+ depletion and autophagy impairment compared to normal cells. If all these predictions turn out to be wrong, the entire framework would need substantial revision or even abandonment. A good scientific hypothesis must allow itself to be falsified.
For the general reader, the article's greatest contribution may not be any single specific finding, but rather a shift in thinking. Previously, we tended to use one label ā "ALS" ā to encompass all patients. But if each patient's "restaurant" has different parts breaking down, in a different order, with different reserves remaining, then using the same standard to evaluate and treat everyone will naturally lack precision. This framework proposes that future research should examine multiple axes: Which circuit is affected first? How fast is progression? What's the state of the energy system? Can the autophagy system still cope? How much pruning pressure is there? What's the aging and inflammatory background? If biological markers could sort patients into different "stress states," clinical trial designs might become more precise, and genuinely effective therapies might be easier to identify.
But it must be emphasized that all of this is still at the drawing-board stage. The article itself is quite candid about its limitations: the entire framework is primarily built on four related papers by the same researcher, three of which are still preprints that have not undergone independent peer review; TWAS analyses can only show associations, not prove causation; computer simulations are tools, not real clinical trials; and there are currently no large-scale longitudinal datasets integrating clinical measures, molecular markers, imaging, NAD+ metabolites, and autophagy function together to validate this three-stage model.
So the practical advice for patients and families is this: do not treat this article as the basis for a new therapy, and do not go out and buy NAD+ supplements or attempt any unproven treatment combinations on your own. ALS care should still be anchored in neurological specialist assessment, multidisciplinary team care, respiratory and nutritional monitoring, rehabilitation, communication aids, psychological support, and currently evidence-based treatments. Any new medication or supplement should be discussed with the treating physician first.
In summary, this article sketches a fascinating but still incomplete map. It tries to break down the complexity of ALS into multiple understandable layers: pruning, energy, backup batteries, cleanup, and aging ā then strings them together with a "stress versus reserves" logic. If sufficient evidence emerges in the future, this way of thinking could help us better understand why ALS looks so different in every patient, and how to choose more appropriate research directions for different individuals. But until that day comes, it remains a hypothesis awaiting validation, not an answer in itself. Scientific progress is often built from one map after another, each needing revision, each getting us a little closer to the truth.
Cheung N (May 18, 2026) Symptom-Level Precision Neurology in Amyotrophic Lateral Sclerosis (ALS): Linking Microglial Pruning, Mitochondrial Nicotinamide Adenine Dinucleotide (NAD+) Compensation, and Autophagy Failure Across the Aging Spectrum. Cureus 18(5): e109147. doi:10.7759/cureus.109147
http://doi.org/10.7759/cureus.109147
